BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova to Participate in Two Investor Conferences in September

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO,

Related news

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

AXSMAxsome2026-09-02 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

CLNNClene Inc.2026-09-03 12:00 EST

Clene to Present at Upcoming September Investor Conferences

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

MNOVMediciNova2026-06-08 12:00 EST

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MNOVMediciNova2026-05-26 23:00 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Stock data

Close
3.45 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States